Noa Krugliak Cleveland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Noa Krugliak Cleveland has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- David T. Rubin
University of Chicago Medicine Inflammatory Bowel Disease Center , Chicago, IL 60637
8 shared publications - Amelia Kellar
Department of Medicine, University of Chicago Medicine Inflammatory Bowel Disease Center , Chicago, IL 60637
3 shared publications - Joëlle St-Pierre
IBD Unit, Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary , Calgary, Alberta, T2N 4Z6
3 shared publications Benjamin Chastek
Optum, Eden Prairie, USA
2 shared publications- Benjamin D. McDonald
Department of Medicine, University of Chicago, Chicago, IL, USA
2 shared publications - Charlotte M. Duty
Inflammatory Bowel Disease Center University of Chicago Medicine Chicago Illinois USA
2 shared publications
Latest Publications
- Open Access
Isolated Mild Hyperemia Identified by Intestinal Ultrasound Is Associated With Adverse Outcomes in Inflammatory Bowel Disease
Background: Increased bowel wall thickness (BWT) measured by intestinal ultrasound (IUS) is the most predictive sonographic parameter of endoscopic disease activity in Crohn's disease (CD) and ulcerative colitis (UC). The clinical significance of hyperemia in the absence of increased BWT has yet to be delineated. The aim of this study is to assess whether isolated hyperemia on IUS correlates with adverse disease outcomes (ADOs). Methods: We conducted a retrospective cohort study of IBD patients who underwent IUS between 7/18/2022 and 5/7/2024. Patients with normal BWT (≤ 3.0 mm) + mild hyperemia (modified Limberg (mLimberg) 1) or no hyperemia (mLimberg 0) were included. Primary outcome was ADO within 12 months, defined as medication change or escalation, corticosteroid use, surgery, or hospitalization. Secondary outcome was the frequency of active disease by sonographic, endoscopic, or biochemical parameters within 12 months of the index IUS assessment. Additional secondary outcomes included the comparison of the frequency of ADOs between patients with mLimberg 1 in one bowel segment versus mLimberg 1 in two or three bowel segments on index IUS. Survival probabilities were compared using Kaplan–Meier analysis with log‐rank tests. Results: 128 patients were included; 67 with mLimberg 1 (55 CD, 12 UC) and 61 with mLimberg 0 (52 CD, 9 UC). ADOs were seen in 3 months, 6, and 12 months in the mLimberg 1 versus the mLimberg 0 cohort in 28.4% versus 11.5%, 41.8% versus 24.6%, and 53.7% versus 31.1%, respectively ( p = 0.0166). The median time to ADO in the mLimberg 1 versus mLimberg 0 was 66.5 versus 136.5 days ( p = 0.017). Conclusion: Isolated mild hyperemia on IUS is associated with ADOs and may warrant consideration in clinical decision‐making, treatment optimization, and future treat‐to‐target strategies.
Open AccessIsolated Mild Hyperemia Identified by Intestinal Ultrasound Is Associated With Adverse Outcomes in Inflammatory Bowel Disease
Background: Increased bowel wall thickness (BWT) measured by intestinal ultrasound (IUS) is the most predictive sonographic parameter of endoscopic disease activity in Crohn's disease (CD) and ulcerative colitis (UC). The clinical significance of hyperemia in the absence of increased BWT has yet to be delineated. The aim of this study is to assess whether isolated hyperemia on IUS correlates with adverse disease outcomes (ADOs). Methods: We conducted a retrospective cohort study of IBD patients who underwent IUS between 7/18/2022 and 5/7/2024. Patients with normal BWT (≤ 3.0 mm) + mild hyperemia (modified Limberg (mLimberg) 1) or no hyperemia (mLimberg 0) were included. Primary outcome was ADO within 12 months, defined as medication change or escalation, corticosteroid use, surgery, or hospitalization. Secondary outcome was the frequency of active disease by sonographic, endoscopic, or biochemical parameters within 12 months of the index IUS assessment. Additional secondary outcomes included the comparison of the frequency of ADOs between patients with mLimberg 1 in one bowel segment versus mLimberg 1 in two or three bowel segments on index IUS. Survival probabilities were compared using Kaplan–Meier analysis with log‐rank tests. Results: 128 patients were included; 67 with mLimberg 1 (55 CD, 12 UC) and 61 with mLimberg 0 (52 CD, 9 UC). ADOs were seen in 3 months, 6, and 12 months in the mLimberg 1 versus the mLimberg 0 cohort in 28.4% versus 11.5%, 41.8% versus 24.6%, and 53.7% versus 31.1%, respectively ( p = 0.0166). The median time to ADO in the mLimberg 1 versus mLimberg 0 was 66.5 versus 136.5 days ( p = 0.017). Conclusion: Isolated mild hyperemia on IUS is associated with ADOs and may warrant consideration in clinical decision‐making, treatment optimization, and future treat‐to‐target strategies.
- 9 June 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (11) , 2800-2804
Impact of Upadacitinib on Cardiovascular Events and Lipid Values in Older Inflammatory Bowel Disease Patients With Baseline Cardiovascular Risk
INTRODUCTION: Regulatory safety warnings for Janus kinase inhibitors, based on increased cardiovascular events in the rheumatoid arthritis populations, have raised concern regarding their use in inflammatory bowel disease (IBD) patients with cardiovascular risk factors. METHODS: Patients 50 years and older with IBD initiating upadacitinib were studied. Lipids, atherosclerotic cardiovascular disease risk scores, and adverse events were longitudinally assessed. RESULTS: Low-density lipoprotein increased early but stabilized, whereas high-density lipoprotein increased, with no change in low-density lipoprotein:high-density lipoprotein ratio. Atherosclerotic cardiovascular disease risk increased modestly (+1.2%). No major adverse cardiovascular events occurred. Two venous thromboembolism events occurred during active disease. DISCUSSION: In older patients with IBD and baseline cardiovascular risk, upadacitinib was not associated with cardiovascular events over 188 patient-years, supporting appropriate clinical use with risk monitoring.
- 9 June 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (11) , 2800-2804
Impact of Upadacitinib on Cardiovascular Events and Lipid Values in Older Inflammatory Bowel Disease Patients With Baseline Cardiovascular Risk
INTRODUCTION: Regulatory safety warnings for Janus kinase inhibitors, based on increased cardiovascular events in the rheumatoid arthritis populations, have raised concern regarding their use in inflammatory bowel disease (IBD) patients with cardiovascular risk factors. METHODS: Patients 50 years and older with IBD initiating upadacitinib were studied. Lipids, atherosclerotic cardiovascular disease risk scores, and adverse events were longitudinally assessed. RESULTS: Low-density lipoprotein increased early but stabilized, whereas high-density lipoprotein increased, with no change in low-density lipoprotein:high-density lipoprotein ratio. Atherosclerotic cardiovascular disease risk increased modestly (+1.2%). No major adverse cardiovascular events occurred. Two venous thromboembolism events occurred during active disease. DISCUSSION: In older patients with IBD and baseline cardiovascular risk, upadacitinib was not associated with cardiovascular events over 188 patient-years, supporting appropriate clinical use with risk monitoring.
- Open Access
- 29 April 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (2)
Intestinal Ultrasound in Acute Severe Ulcerative Colitis Treated with Intravenous Cyclosporine: Case Series
Background: Intestinal ultrasound (IUS) has been studied to assess therapeutic response in patients with acute severe ulcerative colitis (ASUC). However, there is no data on sonographic changes occurring in ASUC receiving intravenous (IV) cyclosporine. This case series aims to describe the sonographic changes occurring in hospitalized patients with ASUC receiving IV cyclosporine as salvage therapy. Methods: This is a retrospective observational study in a single tertiary care center from February 2023 to May 2024. Serial sonographic findings of patients with severe UC treated with IV cyclosporine were collected. Sonographic changes associated with clinical outcomes were analyzed. Outcomes included clinical response (Simple Clinical Colitis Activity Index decrease ≤ 3 at day 3 with discharge on oral cyclosporine) and colectomy. Results: Nine patients received IV cyclosporine with IUS monitoring; 67% failed ≥2 advanced therapies. Four responded to cyclosporine, four underwent colectomy, and one switched to upadacitinib with subsequent response during the same admission. Clinical responders had a median 31.8% (IQR 26.3-51.2%) reduction in bowel wall thickness (BWT) and 1-scale reduction in modified Limberg score, whereas non-responders demonstrated 7.2% (IQR-54.8-9.0%) reduction in BWT and no change in modified Limberg score. The median time to clinical response was 2.5 days (IQR 1.8-2.6). Baseline BWT was similar between responders and non-responders: 5.2 mm (IQR 3.5-6.5) versus 5.2 mm (3.8-6.7). Conclusions: A median 31.8% BWT reduction was observed by day 3 among responders, highlighting early sonographic changes associated with response to IV cyclosporine therapy in refractory ASUC.
- 29 April 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (2)
Open AccessIntestinal Ultrasound in Acute Severe Ulcerative Colitis Treated with Intravenous Cyclosporine: Case Series
Background: Intestinal ultrasound (IUS) has been studied to assess therapeutic response in patients with acute severe ulcerative colitis (ASUC). However, there is no data on sonographic changes occurring in ASUC receiving intravenous (IV) cyclosporine. This case series aims to describe the sonographic changes occurring in hospitalized patients with ASUC receiving IV cyclosporine as salvage therapy. Methods: This is a retrospective observational study in a single tertiary care center from February 2023 to May 2024. Serial sonographic findings of patients with severe UC treated with IV cyclosporine were collected. Sonographic changes associated with clinical outcomes were analyzed. Outcomes included clinical response (Simple Clinical Colitis Activity Index decrease ≤ 3 at day 3 with discharge on oral cyclosporine) and colectomy. Results: Nine patients received IV cyclosporine with IUS monitoring; 67% failed ≥2 advanced therapies. Four responded to cyclosporine, four underwent colectomy, and one switched to upadacitinib with subsequent response during the same admission. Clinical responders had a median 31.8% (IQR 26.3-51.2%) reduction in bowel wall thickness (BWT) and 1-scale reduction in modified Limberg score, whereas non-responders demonstrated 7.2% (IQR-54.8-9.0%) reduction in BWT and no change in modified Limberg score. The median time to clinical response was 2.5 days (IQR 1.8-2.6). Baseline BWT was similar between responders and non-responders: 5.2 mm (IQR 3.5-6.5) versus 5.2 mm (3.8-6.7). Conclusions: A median 31.8% BWT reduction was observed by day 3 among responders, highlighting early sonographic changes associated with response to IV cyclosporine therapy in refractory ASUC.
- 1 January 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (Supplement)
P1039Effectiveness and Safety of GLP-1 Receptor Agonists in Reducing Ostomy Output Among IBD Patients with Ileostomies
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used therapies for weight management and type 2 diabetes. The effect of GLP-1RAs on reduction of gastrointestinal motility is well described. Inflammatory bowel disease (IBD) patients with ileostomies often suffer from high ostomy output. We hypothesized that GLP-1RAs can reduce ostomy output in IBD patients with an ileostomy. Methods: We performed a retrospective analysis of IBD patients with ileostomies created at the University of Chicago between April 2021-April 2025 and who were subsequently prescribed GLP-1RAs. Primary analysis was ostomy output before and after starting a GLP1-RA defined as patient-reported frequency of ostomy appliance emptying. Secondary analysis included changes in body mass index (BMI), change in disease activity (active disease defined as C-reactive protein (CRP) >5 mg/L or per endoscopic report), and safety including adverse events (AEs) of specific interest (pancreatitis, bowel obstruction or ileus, and gallbladder disease). Results: 13 (7 CD, 5 UC, 1 IBD-U) patients were included. 12 patients had end ileostomies, and 1 patient had a loop ileostomy. 6 (46.2%) patients had type 2 diabetes, 4 (30.8%) had hypertension, and 1 (7.7%) had hyperlipidemia at baseline. 6 patients were on an IBD therapy at baseline. 11 patients were initiated on semaglutide and 2 were initiated on tirzepatide. 11 patients were prescribed GLP-1RAs for weight management, 6 for type 2 diabetes management, and 4 for high ostomy output in addition to either weight or diabetes management. Median time to follow up from GLP-1RAs start was 340 days (IQR 232-376). Median number of ostomy emptyings per day was 6 (IQR 4.5-8.5), which decreased to 4 (4-4.5) at follow up, P = 0.0139. Median BMI at baseline was 32.5 kg/m2 (IQR 28.6-40.3) and median follow up BMI was 29.95 kg/m2 (IQR 25.47-33.8). 3 (23.1%) patients had active IBD by an objective marker before GLP-1RA start; 2 per CRP and 1 per ileoscopy. Of the 6 patients with at least one follow up objective measure of disease activity (5 CRP, 1 ileoscopy), 0 had evidence of active disease. No patient changed IBD therapy during follow-up. Drug-related AEs included nausea (n = 3), abdominal pain (n = 3), dry mouth (n = 1), and dehydration (n = 1). Two patients had bowel obstructions related to peristomal hernias that were not deemed to be related to the GLP1-RA. No AEs of special interest were reported. (Table 1). Conclusion: GLP-1RAs in IBD patients with ileostomy appear to be effective in reducing ostomy output, BMI reduction, and are generally well tolerated. Conflict of interest: Duty, Charlotte M.: No conflict of interest Bhondwe, Khushi: No conflict of interest Pekow, Joel R.: CVS Health - Consulting Abbvie, Eli Lilly, Pfizer, Johnson and Johnson - Stocks Cohen, Russell: Personal Fees: Abbvie, Celgene, Eli Lilly, Hospira, Janssen, Pfizer, Sandoz Biopharma, Takeda, UCB Pharma Non-financial Support: Abbvie Rubin, David T.: Grant support: Takeda Pharmaceuticals Consultant: Abbvie, Abivax SA, Altrubio, Athos Therapeutics, Inc, Bristol-Myers Squibb, Celltrion, Connect BioPharma, Eli Lilly & Co., Genentech (Roche) Inc., Iterative Health, Janssen Pharmaceuticals, Johnson & Johnson, Merck & Co., Mirador, Odyssey Therapeutics, Pfizer, Sanofi, Spyre, Takeda Pharmaceuticals, Vedanta Biosciences, and Ventyx. Dr. Krugliak Cleveland, Noa: Consultant for NeuroLogica, Johnson & Johnson, GE HealthCare, Abbive Inc., and Sanofi
- 1 January 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (Supplement)
P1039Effectiveness and Safety of GLP-1 Receptor Agonists in Reducing Ostomy Output Among IBD Patients with Ileostomies
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used therapies for weight management and type 2 diabetes. The effect of GLP-1RAs on reduction of gastrointestinal motility is well described. Inflammatory bowel disease (IBD) patients with ileostomies often suffer from high ostomy output. We hypothesized that GLP-1RAs can reduce ostomy output in IBD patients with an ileostomy. Methods: We performed a retrospective analysis of IBD patients with ileostomies created at the University of Chicago between April 2021-April 2025 and who were subsequently prescribed GLP-1RAs. Primary analysis was ostomy output before and after starting a GLP1-RA defined as patient-reported frequency of ostomy appliance emptying. Secondary analysis included changes in body mass index (BMI), change in disease activity (active disease defined as C-reactive protein (CRP) >5 mg/L or per endoscopic report), and safety including adverse events (AEs) of specific interest (pancreatitis, bowel obstruction or ileus, and gallbladder disease). Results: 13 (7 CD, 5 UC, 1 IBD-U) patients were included. 12 patients had end ileostomies, and 1 patient had a loop ileostomy. 6 (46.2%) patients had type 2 diabetes, 4 (30.8%) had hypertension, and 1 (7.7%) had hyperlipidemia at baseline. 6 patients were on an IBD therapy at baseline. 11 patients were initiated on semaglutide and 2 were initiated on tirzepatide. 11 patients were prescribed GLP-1RAs for weight management, 6 for type 2 diabetes management, and 4 for high ostomy output in addition to either weight or diabetes management. Median time to follow up from GLP-1RAs start was 340 days (IQR 232-376). Median number of ostomy emptyings per day was 6 (IQR 4.5-8.5), which decreased to 4 (4-4.5) at follow up, P = 0.0139. Median BMI at baseline was 32.5 kg/m2 (IQR 28.6-40.3) and median follow up BMI was 29.95 kg/m2 (IQR 25.47-33.8). 3 (23.1%) patients had active IBD by an objective marker before GLP-1RA start; 2 per CRP and 1 per ileoscopy. Of the 6 patients with at least one follow up objective measure of disease activity (5 CRP, 1 ileoscopy), 0 had evidence of active disease. No patient changed IBD therapy during follow-up. Drug-related AEs included nausea (n = 3), abdominal pain (n = 3), dry mouth (n = 1), and dehydration (n = 1). Two patients had bowel obstructions related to peristomal hernias that were not deemed to be related to the GLP1-RA. No AEs of special interest were reported. (Table 1). Conclusion: GLP-1RAs in IBD patients with ileostomy appear to be effective in reducing ostomy output, BMI reduction, and are generally well tolerated. Conflict of interest: Duty, Charlotte M.: No conflict of interest Bhondwe, Khushi: No conflict of interest Pekow, Joel R.: CVS Health - Consulting Abbvie, Eli Lilly, Pfizer, Johnson and Johnson - Stocks Cohen, Russell: Personal Fees: Abbvie, Celgene, Eli Lilly, Hospira, Janssen, Pfizer, Sandoz Biopharma, Takeda, UCB Pharma Non-financial Support: Abbvie Rubin, David T.: Grant support: Takeda Pharmaceuticals Consultant: Abbvie, Abivax SA, Altrubio, Athos Therapeutics, Inc, Bristol-Myers Squibb, Celltrion, Connect BioPharma, Eli Lilly & Co., Genentech (Roche) Inc., Iterative Health, Janssen Pharmaceuticals, Johnson & Johnson, Merck & Co., Mirador, Odyssey Therapeutics, Pfizer, Sanofi, Spyre, Takeda Pharmaceuticals, Vedanta Biosciences, and Ventyx. Dr. Krugliak Cleveland, Noa: Consultant for NeuroLogica, Johnson & Johnson, GE HealthCare, Abbive Inc., and Sanofi
- Open Access
- 24 December 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (3) , 452-460
The Chicago Mesenteric Fat Index: A Novel Metric for Point-of-Care Intestinal Ultrasound Evaluation of Mesenteric Fat Wrapping in Crohn’s Disease
Background: Mesenteric fat (MF) wrapping is a characteristic feature of Crohn’s disease (CD). Current assessment methods are limited to binary classification (presence/absence), restricting their utility in assessing disease progression and treatment response. This study aimed to develop and validate a novel semi-quantitative metric for grading MF wrapping using intestinal ultrasound (IUS), and to evaluate its reliability and clinical relevance. Methods: This cross-sectional study included 95 ultrasound scans from 63 patients with CD. The novel index described here categorized MF wrapping into 3 categories: none, incomplete, and complete. Images were independently assessed to evaluate inter- and intrarater reliability. Associations between MF wrapping and clinical characteristics, inflammatory markers, and IUS parameters were analyzed. Results: Interrater reliability for the MF index was moderate (κ = 0.452), while intrarater reliability was substantial (κ = 0.653), similar to binary assessment (κ = 0.572 and κ = 0.674 for inter- and intrarater reliability, respectively). MF wrapping was significantly associated with increased bowel wall thickness (OR, 6.74; P < .001), loss of bowel wall stratification (OR, 22.05; P < .001), hyperemia (OR, 8.09; P = .002), and presence of strictures (OR, 4.30; P = .002). Smoking status and lower serum albumin were significantly associated with increased MF wrapping. Conclusions: CMFI represents a proof-of-concept tool for semi-quantitative assessment of MF wrapping on IUS. While reproducible and associated with other disease markers, its incremental clinical utility remains to be established through prospective validation and longitudinal outcome studies.
- 24 December 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (3) , 452-460
Open AccessThe Chicago Mesenteric Fat Index: A Novel Metric for Point-of-Care Intestinal Ultrasound Evaluation of Mesenteric Fat Wrapping in Crohn’s Disease
Background: Mesenteric fat (MF) wrapping is a characteristic feature of Crohn’s disease (CD). Current assessment methods are limited to binary classification (presence/absence), restricting their utility in assessing disease progression and treatment response. This study aimed to develop and validate a novel semi-quantitative metric for grading MF wrapping using intestinal ultrasound (IUS), and to evaluate its reliability and clinical relevance. Methods: This cross-sectional study included 95 ultrasound scans from 63 patients with CD. The novel index described here categorized MF wrapping into 3 categories: none, incomplete, and complete. Images were independently assessed to evaluate inter- and intrarater reliability. Associations between MF wrapping and clinical characteristics, inflammatory markers, and IUS parameters were analyzed. Results: Interrater reliability for the MF index was moderate (κ = 0.452), while intrarater reliability was substantial (κ = 0.653), similar to binary assessment (κ = 0.572 and κ = 0.674 for inter- and intrarater reliability, respectively). MF wrapping was significantly associated with increased bowel wall thickness (OR, 6.74; P < .001), loss of bowel wall stratification (OR, 22.05; P < .001), hyperemia (OR, 8.09; P = .002), and presence of strictures (OR, 4.30; P = .002). Smoking status and lower serum albumin were significantly associated with increased MF wrapping. Conclusions: CMFI represents a proof-of-concept tool for semi-quantitative assessment of MF wrapping on IUS. While reproducible and associated with other disease markers, its incremental clinical utility remains to be established through prospective validation and longitudinal outcome studies.
- Open Access
- 6 November 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (3) , 444-451
Reliability and Validity of Mesenteric Fat Assessment by Intestinal Ultrasound in Pediatric Crohn’s Disease Using the Chicago Mesenteric Fat Index
Background: Intestinal ultrasound (IUS) provides a noninvasive means of assessing Crohn’s disease (CD), including visualization of mesenteric fat (MF) wrapping. Reliability of MF assessment and correlation with disease activity biomarkers in children is unknown. This study assessed the interrater reliability (IRR) of a binary assessment and a novel semi-quantitative index for grading MF wrapping using IUS (Chicago Mesenteric Fat Index [CMFI]) and correlation with disease activity biomarkers in pediatric patients with CD. Methods: Children (≤18 years of age) with ileal CD who underwent IUS at 2 centers were enrolled. Three expert sonographers independently graded MF as present/absent and by the CMFI. IRR was calculated using Fleiss’ kappa coefficient. Correlations between MF and clinical characteristics, inflammatory markers, and IUS data were calculated. Results: Eighty IUS exams in 67 patients were included. The IRR was substantial for binary MF (κ = 0.744) and CMFI (κ = 0.618). Increasing CMFI grade was associated with bowel wall thickness (P < .001; odds ratio [OR], 16.35; 95% confidence interval [CI], 5.74-46.58), presence of ileal stricture (P < .001; OR, 30.32; 95% CI, 5.74-160.15), and presence of hyperemia (P = .001; OR, 6.59; 95% CI, 2.27-19.09). Conclusion: Assessment of MF on IUS is reproducible and reliable in pediatric CD. The CMFI can be used as a biomarker that mirrors biochemical and sonographic indicators of pediatric CD activity.
- 6 November 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (3) , 444-451
Open AccessReliability and Validity of Mesenteric Fat Assessment by Intestinal Ultrasound in Pediatric Crohn’s Disease Using the Chicago Mesenteric Fat Index
Background: Intestinal ultrasound (IUS) provides a noninvasive means of assessing Crohn’s disease (CD), including visualization of mesenteric fat (MF) wrapping. Reliability of MF assessment and correlation with disease activity biomarkers in children is unknown. This study assessed the interrater reliability (IRR) of a binary assessment and a novel semi-quantitative index for grading MF wrapping using IUS (Chicago Mesenteric Fat Index [CMFI]) and correlation with disease activity biomarkers in pediatric patients with CD. Methods: Children (≤18 years of age) with ileal CD who underwent IUS at 2 centers were enrolled. Three expert sonographers independently graded MF as present/absent and by the CMFI. IRR was calculated using Fleiss’ kappa coefficient. Correlations between MF and clinical characteristics, inflammatory markers, and IUS data were calculated. Results: Eighty IUS exams in 67 patients were included. The IRR was substantial for binary MF (κ = 0.744) and CMFI (κ = 0.618). Increasing CMFI grade was associated with bowel wall thickness (P < .001; odds ratio [OR], 16.35; 95% confidence interval [CI], 5.74-46.58), presence of ileal stricture (P < .001; OR, 30.32; 95% CI, 5.74-160.15), and presence of hyperemia (P = .001; OR, 6.59; 95% CI, 2.27-19.09). Conclusion: Assessment of MF on IUS is reproducible and reliable in pediatric CD. The CMFI can be used as a biomarker that mirrors biochemical and sonographic indicators of pediatric CD activity.
- Open Access
- 23 July 2025
- Published by Science Publishing Group in International Journal of Gastroenterology
- Vol. 9 (2) , 90-93
Rethinking Intra-operative Management of Crohn’s Disease: Intestinal Ultrasound Detects Microscopic Disease Unidentified at Ileal Margin Resection
Crohn’s disease is a chronic and relapsing inflammatory condition that often requires surgical intervention. Post-operative recurrence of Crohn’s disease remains common after surgery occurring in up to 75% of patients. The role of disease-free surgical margins in post-operative recurrence has been debated, however, it has been identified as an independent risk factor for recurrence. We present a case of a woman with obstructive Crohn’s disease who underwent ileocecectomy and was maintained on uninterrupted infliximab therapy. Despite operative and pathology reports describing grossly normal surgical margins, three months post-operation the patient was experiencing new intermittent lower abdominal pain and intestinal ultrasound revealed active ileitis involving a 10cm segment immediately proximal to the ileocolonic anastomosis. Due to concern of incomplete resection, microscopic re-evaluation of the margins was conducted and confirmed histologically positive margins of active Crohn’s disease. Current guidelines have called for additional studies to examine the role of disease-free margins. Our case demonstrates the limitations of gross evaluation of disease-free margins and suggests a potential application of intestinal ultrasound intraoperatively for such assessment. While intestinal ultrasound has been utilized intraoperatively for colonic malignant margin identification, it has not yet been studied in inflammatory bowel disease and requires further evaluation.
- 23 July 2025
- Published by Science Publishing Group in International Journal of Gastroenterology
- Vol. 9 (2) , 90-93
Open AccessRethinking Intra-operative Management of Crohn’s Disease: Intestinal Ultrasound Detects Microscopic Disease Unidentified at Ileal Margin Resection
Crohn’s disease is a chronic and relapsing inflammatory condition that often requires surgical intervention. Post-operative recurrence of Crohn’s disease remains common after surgery occurring in up to 75% of patients. The role of disease-free surgical margins in post-operative recurrence has been debated, however, it has been identified as an independent risk factor for recurrence. We present a case of a woman with obstructive Crohn’s disease who underwent ileocecectomy and was maintained on uninterrupted infliximab therapy. Despite operative and pathology reports describing grossly normal surgical margins, three months post-operation the patient was experiencing new intermittent lower abdominal pain and intestinal ultrasound revealed active ileitis involving a 10cm segment immediately proximal to the ileocolonic anastomosis. Due to concern of incomplete resection, microscopic re-evaluation of the margins was conducted and confirmed histologically positive margins of active Crohn’s disease. Current guidelines have called for additional studies to examine the role of disease-free margins. Our case demonstrates the limitations of gross evaluation of disease-free margins and suggests a potential application of intestinal ultrasound intraoperatively for such assessment. While intestinal ultrasound has been utilized intraoperatively for colonic malignant margin identification, it has not yet been studied in inflammatory bowel disease and requires further evaluation.
- 4 February 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Intestinal Ultrasound Identified Crohn’s Disease In Previously Undiagnosed Siblings
Lay Summary: We present the clinical cases of 3 brothers, 1 with confirmed diagnosis of Crohn’s disease (CD) and 2 with inconclusive findings by endoscopy and histology and demonstrate the utility of intestinal ultrasound in confirming the diagnosis of CD.
- 4 February 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Intestinal Ultrasound Identified Crohn’s Disease In Previously Undiagnosed Siblings
Lay Summary: We present the clinical cases of 3 brothers, 1 with confirmed diagnosis of Crohn’s disease (CD) and 2 with inconclusive findings by endoscopy and histology and demonstrate the utility of intestinal ultrasound in confirming the diagnosis of CD.
- Open Access
- 17 September 2024
- Published by Springer Nature in BMC Gastroenterology
- Vol. 24 (1) , 1-12
Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY
Patients with inflammatory bowel disease (IBD) are at risk of developing dysplasia and, subsequently, colorectal cancer (CRC) owing to chronic inflammation. Patients may also experience other severe disease complications, such as hospitalization and surgery. Several biologics are available for the treatment of patients with IBD and some patients require multiple lines of treatment owing to loss of response or tolerability to their prescribed biologic. Previous studies suggest that the choice of initial biologic treatment may impact the outcomes of later treatment lines. In this study, we assessed adverse clinical outcomes in patients with Crohn’s disease (CD) or ulcerative colitis (UC) who received different biologic treatment sequences. ROTARY part B was a retrospective cohort study using the Optum® Clinical Database that evaluated the incidences of IBD-related hospitalization, IBD-related surgery, dysplasia, CRC, and infections in patients with CD or UC who received two biologics successively. First-line biologics included adalimumab, infliximab, ustekinumab (CD only), and vedolizumab; second-line biologics included infliximab and adalimumab. In patients with CD, the treatment sequence of ustekinumab to infliximab was associated with the highest overall incidences of hospitalization (51.9%), surgery (40.7%), CRC (3.7%), and infection (37.0%). Vedolizumab followed by an anti-tumor necrosis factor alpha (anti-TNFα) treatment was associated with a significantly lower risk of experiencing an adverse medical event (hospitalization, surgery, or infection) than two successive anti-TNFα treatments (odds ratio, 1.526; 95% confidence interval, 1.004–2.320; P < 0.05). In patients with UC, the treatment sequence of vedolizumab to adalimumab resulted in the lowest overall incidence of adverse outcomes (20.3%, 6.3%, 0.0%, 6.3%, and 4.7% for hospitalization, surgery, CRC, dysplasia, and infection, respectively). We describe differences in adverse clinical outcomes associated with sequencing of biologics in patients with CD or UC and demonstrate favorable results in patients who received vedolizumab as a first-line biologic. These results provide potential guidance to clinicians choosing sequences of biologic treatments in patients with IBD.
- 17 September 2024
- Published by Springer Nature in BMC Gastroenterology
- Vol. 24 (1) , 1-12
Open AccessEvaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY
Patients with inflammatory bowel disease (IBD) are at risk of developing dysplasia and, subsequently, colorectal cancer (CRC) owing to chronic inflammation. Patients may also experience other severe disease complications, such as hospitalization and surgery. Several biologics are available for the treatment of patients with IBD and some patients require multiple lines of treatment owing to loss of response or tolerability to their prescribed biologic. Previous studies suggest that the choice of initial biologic treatment may impact the outcomes of later treatment lines. In this study, we assessed adverse clinical outcomes in patients with Crohn’s disease (CD) or ulcerative colitis (UC) who received different biologic treatment sequences. ROTARY part B was a retrospective cohort study using the Optum® Clinical Database that evaluated the incidences of IBD-related hospitalization, IBD-related surgery, dysplasia, CRC, and infections in patients with CD or UC who received two biologics successively. First-line biologics included adalimumab, infliximab, ustekinumab (CD only), and vedolizumab; second-line biologics included infliximab and adalimumab. In patients with CD, the treatment sequence of ustekinumab to infliximab was associated with the highest overall incidences of hospitalization (51.9%), surgery (40.7%), CRC (3.7%), and infection (37.0%). Vedolizumab followed by an anti-tumor necrosis factor alpha (anti-TNFα) treatment was associated with a significantly lower risk of experiencing an adverse medical event (hospitalization, surgery, or infection) than two successive anti-TNFα treatments (odds ratio, 1.526; 95% confidence interval, 1.004–2.320; P < 0.05). In patients with UC, the treatment sequence of vedolizumab to adalimumab resulted in the lowest overall incidence of adverse outcomes (20.3%, 6.3%, 0.0%, 6.3%, and 4.7% for hospitalization, surgery, CRC, dysplasia, and infection, respectively). We describe differences in adverse clinical outcomes associated with sequencing of biologics in patients with CD or UC and demonstrate favorable results in patients who received vedolizumab as a first-line biologic. These results provide potential guidance to clinicians choosing sequences of biologic treatments in patients with IBD.
- Open Access
- 11 December 2023
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 10 (1) , e001182
Role of artificial intelligence in imaging and endoscopy for the diagnosis, monitoring and prognostication of inflammatory bowel disease: a scoping review protocol
Introduction Inflammatory bowel diseases (IBD) are immune-mediated conditions that are increasing in incidence and prevalence worldwide. Their assessment and monitoring are becoming increasingly important, though complex. The best disease control is achieved through tight monitoring of objective inflammatory parameters (such as serum and stool inflammatory markers), cross-sectional imaging and endoscopic assessment. Considering the complexity of the information obtained throughout a patient’s journey, artificial intelligence (AI) provides an ideal adjunct to existing tools to help diagnose, monitor and predict the course of disease of patients with IBD. Therefore, we propose a scoping review assessing AI’s role in diagnosis, monitoring and prognostication tools in patients with IBD. We aim to detect gaps in the literature and address them in future research endeavours. Methods and analysis We will search electronic databases, including Medline, Embase, Cochrane CENTRAL, CINAHL Complete, Web of Science and IEEE Xplore. Two reviewers will independently screen the abstracts and titles first and then perform the full-text review. A third reviewer will resolve any conflict. We will include both observational studies and clinical trials. Study characteristics will be extracted using a data extraction form. The extracted data will be summarised in a tabular format, following the imaging modality theme and the study outcome assessed. The results will have an accompanying narrative review. Ethics and dissemination Considering the nature of the project, ethical review by an institutional review board is not required. The data will be presented at academic conferences, and the final product will be published in a peer-reviewed journal.
- 11 December 2023
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 10 (1) , e001182
Open AccessRole of artificial intelligence in imaging and endoscopy for the diagnosis, monitoring and prognostication of inflammatory bowel disease: a scoping review protocol
Introduction Inflammatory bowel diseases (IBD) are immune-mediated conditions that are increasing in incidence and prevalence worldwide. Their assessment and monitoring are becoming increasingly important, though complex. The best disease control is achieved through tight monitoring of objective inflammatory parameters (such as serum and stool inflammatory markers), cross-sectional imaging and endoscopic assessment. Considering the complexity of the information obtained throughout a patient’s journey, artificial intelligence (AI) provides an ideal adjunct to existing tools to help diagnose, monitor and predict the course of disease of patients with IBD. Therefore, we propose a scoping review assessing AI’s role in diagnosis, monitoring and prognostication tools in patients with IBD. We aim to detect gaps in the literature and address them in future research endeavours. Methods and analysis We will search electronic databases, including Medline, Embase, Cochrane CENTRAL, CINAHL Complete, Web of Science and IEEE Xplore. Two reviewers will independently screen the abstracts and titles first and then perform the full-text review. A third reviewer will resolve any conflict. We will include both observational studies and clinical trials. Study characteristics will be extracted using a data extraction form. The extracted data will be summarised in a tabular format, following the imaging modality theme and the study outcome assessed. The results will have an accompanying narrative review. Ethics and dissemination Considering the nature of the project, ethical review by an institutional review board is not required. The data will be presented at academic conferences, and the final product will be published in a peer-reviewed journal.